Drug Trial Radar · NCT04347473
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Last checked: Nov 20, 2026Latest source record: Apr 15, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Apr 6, 2020
Primary completion
Dec 30, 2020
Study completion Mar 1, 2021
Sponsor
- Lead sponsor
- Psoriasis Treatment Center of Central New JerseyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sun Pharmaceutical Industries Limited
- First posted
- Apr 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
Conditions
- Psoriasis
Interventions
Ilumya Injectable ProductDrug
IL-23 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body surface areaTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.